ES3070493T3 - Methods of treating ribonucleotide reductase-related diseases with a ribonucleotide reductase inhibitor - Google Patents

Methods of treating ribonucleotide reductase-related diseases with a ribonucleotide reductase inhibitor

Info

Publication number
ES3070493T3
ES3070493T3 ES21869378T ES21869378T ES3070493T3 ES 3070493 T3 ES3070493 T3 ES 3070493T3 ES 21869378 T ES21869378 T ES 21869378T ES 21869378 T ES21869378 T ES 21869378T ES 3070493 T3 ES3070493 T3 ES 3070493T3
Authority
ES
Spain
Prior art keywords
dosing
compound
group
day
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES21869378T
Other languages
English (en)
Spanish (es)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES3070493T3 publication Critical patent/ES3070493T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES21869378T 2020-09-15 2021-09-15 Methods of treating ribonucleotide reductase-related diseases with a ribonucleotide reductase inhibitor Active ES3070493T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063078844P 2020-09-15 2020-09-15
PCT/JP2021/033855 WO2022059692A1 (en) 2020-09-15 2021-09-15 Methods of treating ribonucleotide reductase-related diseases with a ribonucleotide reductase inhibitor

Publications (1)

Publication Number Publication Date
ES3070493T3 true ES3070493T3 (en) 2026-06-16

Family

ID=80776678

Family Applications (1)

Application Number Title Priority Date Filing Date
ES21869378T Active ES3070493T3 (en) 2020-09-15 2021-09-15 Methods of treating ribonucleotide reductase-related diseases with a ribonucleotide reductase inhibitor

Country Status (8)

Country Link
US (1) US20230390251A1 (cg-RX-API-DMAC7.html)
EP (1) EP4213842B1 (cg-RX-API-DMAC7.html)
JP (1) JP7828333B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230067647A (cg-RX-API-DMAC7.html)
AU (1) AU2021345171A1 (cg-RX-API-DMAC7.html)
ES (1) ES3070493T3 (cg-RX-API-DMAC7.html)
TW (1) TW202227060A (cg-RX-API-DMAC7.html)
WO (1) WO2022059692A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011121453A2 (en) * 2010-03-30 2011-10-06 Clavis Pharma Asa Methods and compositions for treating or ameliorating cancer using gemcitabine-5'-elaidate
US10889555B2 (en) * 2016-05-31 2021-01-12 Taiho Pharmaceutical Co., Ltd. Sulfonamide compound or salt thereof
TWI748142B (zh) * 2017-11-29 2021-12-01 日商大鵬藥品工業股份有限公司 抗腫瘤劑

Also Published As

Publication number Publication date
JP7828333B2 (ja) 2026-03-11
JP2023541432A (ja) 2023-10-02
AU2021345171A1 (en) 2023-05-25
US20230390251A1 (en) 2023-12-07
AU2021345171A9 (en) 2024-02-08
KR20230067647A (ko) 2023-05-16
EP4213842B1 (en) 2026-04-15
TW202227060A (zh) 2022-07-16
WO2022059692A1 (en) 2022-03-24
EP4213842A1 (en) 2023-07-26
EP4213842A4 (en) 2024-07-17